Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery

2.50
Hdl Handle:
http://hdl.handle.net/10143/193189
Title:
Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery
Authors:
Ringerike, Tove; Hamidi, Vida; Hagen, Gunhild; Reikvam, Åsmund; Klemp, Marianne
Citation:
Rapport fra Kunnskapssenteret 13/2011
Additional Links:
http://kunnskapssenteret.no/Publikasjoner/Thromboprophylactic+treatment+with+rivaroxaban+or+dabigatran+compared+with+enoxaparin+or+dalteparin+in+patients+undergoing+elective+hip-+or+knee+replacement+surgery.12721.cms

Full metadata record

DC FieldValue Language
dc.contributor.authorRingerike, Toveen
dc.contributor.authorHamidi, Vidaen
dc.contributor.authorHagen, Gunhilden
dc.contributor.authorReikvam, Åsmunden
dc.contributor.authorKlemp, Marianneen
dc.date.accessioned2011-12-05T11:03:48Z-
dc.date.available2011-12-05T11:03:48Z-
dc.date.issued2011-06-
dc.identifier.citationRapport fra Kunnskapssenteret 13/2011en
dc.identifier.isbn978-82-8121-414-9-
dc.identifier.issn1890-1298-
dc.identifier.urihttp://hdl.handle.net/10143/193189-
dc.description.abstractENGLISH: 1-page key messages Due to a high risk of thromboembolism in patients undergoing major orthopaedic surgery it has become standard practice to give thromboprophylactic treatment to these patients. Pharmaceutical interventions with or without addition of mechanical methods are recommended. This project, commissioned by Helse Bergen HF Ortopedisk klinikk, examined thromboprophylaxis with rivaroxaban or dabigatran compared with low-molecular weight heparins (LMWH, i.e. enoxaparin and dalteparin) with regard to efficacy, safety and cost-effectiveness in patients undergoing elective total hip or knee replacement surgery. We conducted a systematic review of the literature and made cost-effectiveness analyses based on a model that calculated quality-adjusted life years and life time costs. The main findings were that: •We did not find statistically significant differences between dabigatran and enoxaparin for mortality, pulmonary embolism, deep vein thrombosis or major bleeding. The quality of the evidence ranged from very low to moderate. •For rivaroxaban compared with enoxaparin we found statistically a significant reduction in deep vein thrombosis, but also a trend towards increased risk of major bleeding. For mortality and pulmonary embolism there were no statistically significant differences between treatments. The quality of the evidence ranged from very low to moderate. •Our results indicate a great uncertainty regarding which strategy is the most cost-effective. However, rivaroxaban and enoxaparin had a slightly higher probability of being cost-effective alternatives for patients undergoing total hip or knee replacement, respectively. •The results of our model analysis of the uncertainty surrounding each group of parameters indicated that more research on efficacy data would have the greatest impact on reducing decision uncertainty.en
dc.language.isoenen
dc.publisherNorwegian Knowledge Centre for the Health Servicesen
dc.relation.ispartofseriesRapport fra Kunnskapssentereten
dc.relation.ispartofseries13/2011en
dc.relation.urlhttp://kunnskapssenteret.no/Publikasjoner/Thromboprophylactic+treatment+with+rivaroxaban+or+dabigatran+compared+with+enoxaparin+or+dalteparin+in+patients+undergoing+elective+hip-+or+knee+replacement+surgery.12721.cmsen
dc.subjectVDP::Medisinske Fag: 700en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Ortopedisk kirurgi: 784en
dc.subject.meshOrtopedien
dc.subject.meshArthroplasty, Replacement, Hipen
dc.titleThromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgeryen
dc.title.alternativeTromboseprofylakse ved hofte og kneprotesekirurgien
dc.typepeer revieweden
dc.typeReporten
dc.contributor.departmentNOKCen
All Items in HeRA are protected by copyright, with all rights reserved, unless otherwise indicated.